CD44 and neoplasm: CD44-targeted NIR-PIT in combination with other therapies showed promising results in MC38-luc and LL/2 but was less effective against MOC1 tumor which has low CD44 expression and fewer CD44 positive tumor cells compared to MC38-luc and LL/2.